Boehringer Ingelheim is accepting proposals for the 2021 Advancement in Equine Research Awards for Equine Respiratory Disease Research.
“Boehringer Ingelheim acknowledges the importance of promoting equine research to be able to continue to advocate and provide future resources for horses’ well-being and overall health,” said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim. “As we begin our 11th year of equine research awards, we will continue to focus on the evolving need of research for equine infectious respiratory disease and equine asthma syndrome. Previous award recipients have made great strides in the equine asthma space providing breakthroughs to improve equine health and we wish to continue this research by accepting proposals regarding this topic from both public and private researchers.”
Veterinarians, diagnosticians, public and private researchers in the United States, Canada and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment and understanding of equine disease. Boehringer Ingelheim will present five separate $15,000 awards focused on two specific disease topics.
Proposals must address one of the two following focus areas for consideration:
- Equine Infectious Respiratory Disease
- Equine Asthma Syndrome
Proposals must be submitted by September 15, 2021, and will be reviewed by an independent review board that consists of renowned equine industry professionals, including practicing veterinarians and researchers. The board will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality and scientific quality. The awards will be announced at the 67th annual American Association of Equine Practitioners Convention December 4-8, 2021.
This year Boehringer Ingelheim will accept electronic copies of the proposals in lieu of hard copies. To participate in the 2021 awards program, submit a e-copy proposal, cover letter and curriculum to Dr. Steve Grubbs at email@example.com.
The Boehringer Ingelheim Advancement in Equine Research Awards were launched in 2011 to support veterinary research that results in practical applications for insights into important equine infectious and non-infectious diseases. More than $600,000 has been awarded to date for emerging science in equine research.
For more information and complete submission instructions, please visit www.equinediseaseresearch.com.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.